BioMarin Pharmaceutical | BMRN - Assets


BioMarin Pharmaceutical reported $11.57B in Assets for its fiscal quarter ending in September of 2026.





Assets Change Date
Acadia Pharmaceuticals USD 1.79B 51.25M Sep/2026
Agios Pharmaceuticals USD 1.06B 44.38M Sep/2026
Alnylam Pharmaceuticals USD 7.99B 2.44B Sep/2026
Amgen USD 96.05B 409M Sep/2026
Bayer EUR 113.47B 6.18B Sep/2026
Biogen USD 32.05B 32.5M Sep/2026
BioMarin Pharmaceutical USD 11.57B 154.21M Sep/2026
Gilead Sciences USD 51.41B 2.05B Sep/2026
Incyte USD 7.29B 585.39M Sep/2026
Insmed USD 2.23B 123.49M Sep/2026
Ionis Pharmaceuticals USD 2.91B 81.91M Sep/2026
Moderna USD 13.47B 2.51B Sep/2026
Neurocrine Biosciences USD 5.63B 268.3M Sep/2026
PTC Therapeutics USD 3.21B 42.76M Sep/2026
Puma Biotechnology USD 202.86M 7.95M Sep/2025
Regeneron Pharmaceuticals USD 44.41B 2.67B Sep/2026
Roche Holding CHF 98.2B 2.5B Jun/2026
Sangamo BioSciences USD 97.56M 11.39M Jun/2025
Sanofi EUR 129.06B 1.04B Jun/2026
Sarepta Therapeutics USD 3.17B 22.45M Sep/2026
Ultragenyx Pharmaceutical USD 1.19B 77M Sep/2026
United Therapeutics USD 7.03B 186M Sep/2026
Vertex Pharmaceuticals USD 32.74B 5.31B Sep/2026